Stoke Therapeutics, Inc. (STOK) 株式分析

企業概要

Stoke Therapeutics, Inc. is a biotechnology firm dedicated to developing therapeutic treatments for severe genetic diseases through the upregulation of protein expression. The company operates within the healthcare sector and specifically focuses on the biotechnology industry, utilizing a specialized approach known as Targeted Augmentation of Nuclear Gene Output (TANGO) to develop antisense oligonucleotides (ASOs) that selectively restore protein expression. Currently, the enterprise holds a market capitalization of 20.6 億ドル (2.06B) and employs a workforce of 170 名。The annual revenue generated over the trailing twelve months stands at 1.8442 億ドル (184.42M). These valuation and revenue figures indicate that the company maintains a significant market presence relative to its employee count, suggesting an asset-intensive or high-value intellectual property model typical of the biotechnology industry, despite the revenue figure being lower than its market cap would imply in a mature manufacturing business.

財務健全性

The company reported revenues of 1.8442 億ドル (184.42M) and a net income of -688.5 万ドル (-6,885,000) over the trailing twelve months, while EBITDA was recorded at -1882 万ドル (-18,820,000). The substantial gap between the positive revenue of 1.8442 億ドル and the negative net income of -688.5 万ドル reveals a cost structure characterized by high operating expenses that exceed gross profit, which is consistent with early-stage drug development but indicates a lack of profitability at the current scale. Notably, the company generated positive free cash flow of 330.2 万ドル (33.02M), which provides a degree of financial flexibility by generating internal cash to fund operations despite the reported net loss. The gross margin is listed at 100.0%, indicating that the cost of goods sold is negligible compared to revenue, likely due to the nature of ASO manufacturing or reporting conventions for this stage. Conversely, the operating margin is -4382.2% and the profit margin is -3.7%, figures that reflect significant operating losses relative to sales volume. The company holds cash reserves of 2.8467 億ドル (284.67M) against a debt load of 415 万ドル (4.15M), resulting in a debt-to-equity ratio of 1.18. This disparity between substantial cash holdings and minimal debt suggests a balance sheet that is heavily weighted towards liquidity rather than leverage, although the debt-to-equity ratio technically indicates a leveraged position relative to shareholder equity. The current ratio stands at 5.28, which indicates a very strong short-term liquidity position with current assets far exceeding current liabilities. The return on equity is -2.4% and the return on assets is -3.7%, metrics that reveal that management has not yet generated positive returns on capital deployed, a common characteristic for companies in the R&D phase of the biotechnology lifecycle.

バリュエーション評価

The trailing twelve-month P/E ratio is not available (N/A) due to the lack of net income, whereas the forward P/E ratio is reported as -10.98. The negative forward P/E ratio implies that the market is pricing in expected future earnings based on current valuation multiples, rather than historical profitability. The price-to-book ratio is 5.83, which indicates that the market values the company's equity at a significant premium over its book value, reflecting the high value placed on its intangible assets and intellectual property. The price-to-sales ratio is 11.18, and the EV/EBITDA is -94.69, metrics that suggest the market is willing to pay a high multiple for revenue despite the company's current inability to generate earnings. The stock has reached a 52-week high of 40.22 ドル and a 52-week low of 5.35 ドル. Given the current trading dynamics implied by the valuation metrics, the price action reflects a wide trading range where the current market price sits well below the 52-week high of 40.22 ドル, indicating significant volatility or a correction from recent peaks. The beta is 1.22, which means the stock exhibits higher price volatility than the broader market, moving 22% more than the market average in response to market movements.

Growth & Income

The revenue growth year-over-year is -93.8%, while earnings growth is not available (N/A) due to the absence of prior comparable earnings data. The negative revenue growth rate indicates a contraction in sales, which is a critical factor for investors analyzing the company's commercial trajectory and market capture capabilities. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it is classified as a non-dividend payer that reinvests all available resources into research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by significant revenue contraction and a lack of current profitability or dividend distributions, typical for biotechnology firms focused on pipeline advancement.